NeoRx responds to FDA:
This article was originally published in Clinica
Executive Summary
NeoRx has submitted to the US FDA data from a phase II dosimetry study of its Skeletal Targeted Radiotherapy (STR) technique in patients with multiple myeloma, a cancer of the bone marrow. The dosimetry study was requested by the FDA to validate the patient-specific dosing method the company had used in earlier studies. NeoRx has also submitted to the agency a revised proposal for further clinical development of STR. "We believe that STR offers distinct advantages for transplant-eligible patients with multiple myeloma, a cancer that currently has no cure," says Douglass Given, president and CEO of the Seattle, Washington firm.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.